ARCHIVES

NCI begins rewrite of cancer center grant guidelines; will allow clinical investigator support. Goal is to implement P30-P50 working group recommendations, simplify guidelines, Karen Antman tells advisory board.

This article is from The Cancer Letter archive.

Vol. 30 No. 12 | March 19, 2004

Download PDF Visit The Full Archive

Related Articles

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

January 31, 2003

NCI Leaders, Others Defend Cancer Program Against Bailar’s Charge They Are Losing War Against Cancer

May 16, 1986

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

Proflavine Bioassay Ineffective, NCI Says

July 15, 1977

In Brief: Rosenberg To Give Karnofsky Lecture at ASCO, Minna To Present Rosenthal Lecture At AACR

April 27, 1984

ODAC Recommendation for Pertuzumab Signals FDA’s Resolve In Granting Accelerated Approvals

September 20, 2013